Bio-Thera Solutions and Intas Pharmaceuticals Expand Strategic Biosimilar Partnership in Canada Bio-Thera Solutions announced a broadened collaboration with Intas Pharmaceuticals to commercialize BAT2506, a biosimilar referencing Simponi, in Canada.

Bio-Thera Solutions and Intas Pharmaceuticals Expand Strategic Biosimilar Partnership in Canada #Guangzhou #Canada #Bio-Thera #BAT2506 #Simponi

Bio-Thera Solutions' BAT2506 Receives FDA Acceptance for BLA as a Biosimilar to Simponi® Bio-Thera Solutions announces FDA acceptance of its Biologics License Application for BAT2506, a biosimilar to Simponi®, targeting autoimmune conditions.

Bio-Thera Solutions' BAT2506 Receives FDA Acceptance for BLA as a Biosimilar to Simponi® #China #Guangzhou #Bio-Thera #BAT2506 #Simponi

Bio-Thera Solutions Moves Forward with BAT2506 Biosimilar Application in EU Bio-Thera Solutions has achieved a significant milestone with the acceptance of its biosimilar BAT2506 application by the EMA in the EU.

Bio-Thera Solutions Moves Forward with BAT2506 Biosimilar Application in EU #China #Guangzhou #Bio-Thera_Solutions #BAT2506 #Simponi